Loxo Oncology at Lilly
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Loxo Oncology at Lilly
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
No big buyouts were revealed during the annual J.P. Morgan Healthcare Conference for a third year in a row. Big pharma firms are in acquisition mode, but execs stress desire for easy integrations and scientific alliances.
The pharma is digging deeper with early- and mid-stage R&D in age-related neurodegeneration, diabetes/obesity and other priority areas.
CEO Dave Ricks told investors Lilly will succeed via volume-driven growth of nine key products launched since 2019, which its commitment to lower prices will facilitate.
- Other Names / Subsidiaries
- Loxo Oncology, Inc.